Vaxcyte’s stock price dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an ...

Vaxcyte (PCVX) shared topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, ...

VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of IPD in ...

At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At ...